e-learning
resources
Copenhagen 2005
Tuesday 20.09.2005
Improving asthma control in the harder-to-reach population
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The new approaches to the oral corticosteroid dosage decrease in patients with severe steroid-resistant bronchial asthma
N. L. Shaporova, V. I. Trofimov, O. V. Dudina, I. A. Fedoseeva, D. P. Lebedeva (St. Petersburg, Russian Federation)
Source:
Annual Congress 2005 - Improving asthma control in the harder-to-reach population
Session:
Improving asthma control in the harder-to-reach population
Session type:
Oral Presentation
Number:
3046
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. L. Shaporova, V. I. Trofimov, O. V. Dudina, I. A. Fedoseeva, D. P. Lebedeva (St. Petersburg, Russian Federation). The new approaches to the oral corticosteroid dosage decrease in patients with severe steroid-resistant bronchial asthma. Eur Respir J 2005; 26: Suppl. 49, 3046
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Salmeterol treatment improves corticosteroid responsivness in patients with corticosteroid-insensitive severe asthma
Source: Annual Congress 2005 - Improving asthma control in the harder-to-reach population
Year: 2005
Children with mild asthma: do they benefit from inhaled corticosteroids?
Source: Eur Respir J 2002; 20: 1470-1475
Year: 2002
Corticosteroid sensitivity in patients with chronic obstructive pulmonary disease is restored by theophylline
Source: Annual Congress 2005 - Therapeutic options for COPD: present and future
Year: 2005
Low-dose inhaled and nasal corticosteroid use and the risk of cataracts
Source: Eur Respir J 2006; 27: 1168-1174
Year: 2006
Severe therapy resistant asthma
Source: ISSN=1025-448x, ISBN=1-904097-26-x, page=312
Year: 2003
Nebulizer therapy with budesonide in addition to systemic corticosteroids in acute severe asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 541s
Year: 2004
Bronchodilator therapies for severe asthma
Source: Eur Respir Mon 2011; 51: 253-267
Year: 2011
Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment
Source: Eur Respir J 2006; 27: 964-971
Year: 2006
Oral corticosteroids in the treatment of exacerbation of severe asthma
Source: Virtual Congress 2020 – Exhaled biomarkers of asthma and the asthma burden
Year: 2020
Effect of oral prednisolone on the bronchoprotective effect of formoterol in patients with persistent asthma
Source: Eur Respir J 2001; 17: 374-379
Year: 2001
High or standard initial dose of budesonide to control mild-to-moderate asthma?
Source: Eur Respir J 2001; 17: 856-862
Year: 2001
Where current pharmacological therapies fall short in COPD: symptom control is not enough
Source: Eur Respir Rev 2007; 16: 98-104
Year: 2007
Characterisation of severe, steroid-dependent asthma patients who initiate biologics versus those who do not
Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments
Year: 2021
The oral corticosteroid sparing effect of omalizumab in paediatric patients with severe chronic asthma
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010
The importance of early applying inhaled corticosteroids in patients with mild bronchial asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 57s
Year: 2002
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV
1
in patients with severe persistent allergic asthma irrespective of age
Source: Eur Respir J 2005; 26: Suppl. 49, 48s
Year: 2005
Inhaled corticosteroids and the risk of a first exacerbation in COPD patients
Source: Eur Respir J 2004; 23: 692-697
Year: 2004
Scientific rationale for using a single inhaler for asthma control
Source: Eur Respir J 2007; 29: 587-595
Year: 2007
Biologic therapies in paediatric severe asthma
Source: ERS webinar 2020: Biologic therapies in paediatric severe asthma
Year: 2020
Combined therapy of severe osteoporosis for patients with bronchial asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 47s
Year: 2001
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept